Your session is about to expire
← Back to Search
NM21-1480 for Advanced Cancer
Study Summary
This trial is to test a new cancer drug for safety and effectiveness. The drug will be given to people with advanced solid tumors to see if it is safe and if it works.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have received certain types of immunotherapy within the last 4 weeks before starting the study drug.You have a current autoimmune disease or have had one in the past.You have a type of cancer other than liver or bile duct cancer that has not responded to other treatments, and you have finished previous treatments at least 4 weeks before starting this study.You have advanced lung cancer or other specific solid tumors that have continued to grow despite previous treatments. Your previous treatment must have been finished 2-4 weeks before starting the study.You have had a bad reaction to the inactive ingredients in the medication in the past.You have not received certain standard treatments for your type of cancer, or have not fully recovered from side effects of previous treatment.You have taken any experimental drugs that haven't been approved for use, including drugs targeting CD137/4-1BB, within the specified time frame before starting the study drug.
- Group 1: NM21-1480 Treatment arm
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants will this trial have in total?
"One hundred and forty-seven individuals are needed to partake in this study. These participants must meet the specified inclusion criteria. The trial is being conducted at various sites, such as The University Of Texas MD Anderson Cancer Center in Houston, Texas and Sarah Cannon Cancer Center in Nashville, Tennessee."
Does this experiment only include individuals under the age of 25?
"This study requires that patients be between 18-75 years old, which is a common age range for clinical trials. There are significantly more options available for older adults, with 1891 studies open to people over 65 compared to only 36 for those under 18."
Are patients currently being enrolled in this trial?
"The study, as seen on clinicaltrials.gov, is still recruiting patients. The first posting was on 8/19/2020 with the most recent update being on 5/18/2021."
Are there any requirements to sign up for this experimental program?
"One hundred and forty-seven individuals with advanced solid tumors will be receiving the experimental treatment. To participate in the trial, patients must meet the following conditions: They should have completed their prior therapy 2 to 4 weeks before receiving the first dose of study medication, as specified by protocol according to type of prior therapy; they must have been diagnosed with a solid tumor other than hepatocellular carcinoma or intrahepatic cholangiocarcinoma that is advanced or recurrent and progressing since last anti-tumor therapy, for which no alternative standard therapy exists; finally, patients must have NSCLC or another specified solid"
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger